Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can dropping one blood thinner cut bleeding without raising heart risks?

NCT ID NCT04250116

Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This trial tests whether people with atrial fibrillation who had a stent placed more than a year ago can safely switch from two blood thinners to just one. Participants receive either a single anticoagulant or the same anticoagulant plus clopidogrel for two years. Researchers track deaths, heart attacks, strokes, and bleeding to see which strategy offers the better balance of protection and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A single anticoagulant (apixaban, rivaroxaban, or warfarin) compared with the same anticoagulant plus clopidogrel
What this could lead to
If a single blood thinner works as well as dual therapy, patients could avoid extra bleeding risk while keeping stroke and stent protection.
What could go wrong
This is a Phase 4 trial, so the approach is already used in practice, but the optimal long-term strategy is unproven. Single therapy might raise the risk of stent clots or heart attacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

960 people

The number who actually took part.

Started

Apr 2020

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. over 19 years old 2. Patient who underwent PCI with DES more than 12 months ago 3. Non-valvular atrial fibrillation patients requiring long-term anticoagulation Exclusion Criteria: 1. Over 85 years old 2. Pregnancy or Potential Pregnancy 3. Life expectancy within 1 year 4. Patients who refuse or do not understand the written consent form 5. Requiring anticoagulation due to history of mechanical valve replacement, mitral stenosis or deep vein thrombosis 6. Coagulopathy, continuous bleeding, or Hb level below 10 g/dL 7. Intracerebral hemorrhage within 2 months 8. Patients with gastrointestinal hemorrhage within three months of registration 9. Patients diagnosed with a gastrointestinal tumor that requires continuous treatment 10. Patients treated with 1st generation drug-eluting stents (Cypher, Taxus, or Endeavor Sprint)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • Severance Cardiovascular Hospital, Yonsei University Health System

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.